INTRODUCTION
The PPAR (peroxisome-proliferator-activated receptor) γ is a ligand-dependent transcription factor that is predominantly expressed in adipose tissue, both white and brown [1, 2] . In mouse, there are two PPARγ isoforms, γ 1 and γ 2, which are derived from the same gene, but are transcribed from different promoters [2a] . The expression of the PPARγ 2 isoform is practically restricted to adipose tissue [2] . PPARγ plays an important promoting role in the differentiation of adipocytes [3] . PPARγ heterodimerizes with the 9-cis-retinoic acid receptor, RXRα, and the heterodimer binds to the PPRE (PPAR-response element) [4] . PPREs have been characterized in the promoter/enhancer regions of several genes expressed in adipocytes, such as lipoprotein lipase, aP2 (i.e. fatty acid binding protein) and phosphoenolpyruvate carboxykinase (for review see [5] ). Also the gene for the brownadipose-tissue-specific UCP1 (uncoupling protein 1) contains a PPRE site [6, 7] .
Due to the importance of PPARγ for cell differentiation [8] , significant interest has developed for the use of PPARγ activation as an anticancer treatment in different tissues [9] . Activation of PPARγ in cancer cells is expected to promote differentiation and thus to decrease proliferation. Conversely, during physiologically induced cell proliferation, the opposite effect may be necessary, i.e. to ensure a low activity of PPARγ in order to allow for proliferation instead of differentiation. One such physiologically induced state of cell proliferation occurs during the recruitment process in brown adipose tissue [10] . In brown adipose tissue, noradrenaline promotes both cell proliferation and cell differentiation. From studies of cells in culture, it has been concluded that a switch in the responsiveness to noradrenaline occurs: in brown pre-adipocytes, noradrenaline stimulates proliferation, but in brown adipocytes, noradrenaline advances the differentiation process, both processes being mediated by cAMP [10] . It could thus be proposed that this switch in the ability of noradrenaline to promote these different processes may be associated with a switch in the ability of noradrenaline to influence PPARγ gene expression, from repressing PPARγ gene expression in brown pre-adipocytes to promoting PPARγ gene expression in mature brown adipocytes.
To investigate whether and how noradrenaline influences the expression of the transcription factor PPARγ in brown adipocytes, primary cultures of brown adipocytes were exposed to noradrenaline, the signalling process involved in the control of PPARγ expression was analysed, and the relationship between PPARγ mRNA and protein amounts was examined.
Abbreviations used: CREB, cAMP-response-element-binding protein; DMEM, Dulbecco's modified Eagle's medium; ERK, extracellular-signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; PI3K, phosphoinositide 3-kinase; PKA, protein kinase A; PPAR, peroxisomeproliferator-activated receptor; PPRE, PPAR-response element; TFIIB, transcription factor IIB; UCP1, uncoupling protein 1. 1 To whom correspondence should be addressed (email jan@metabol.su.se).
EXPERIMENTAL Animals, cell isolation and cell culture
Male NMRI mice, purchased from local suppliers (B&K or Eklunds, Stockholm, Sweden), were kept at room temperature (approx. 22
• C) for at least 24 h after arrival. At the age of 4 weeks, the mice were killed by CO 2 , and the brown adipose tissue was isolated from the interscapular, cervical and axillary depots, principally as described in [11] . The pooled tissue pieces were minced in DMEM (Dulbecco's modified Eagle's medium) and transferred to a digestion solution with 0.2 % (w/v) collagenase (type II; Sigma) in a buffer consisting of 0.1 M Hepes (pH 7.4), 123 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 4.5 mM glucose and 1.5 % (w/v) BSA. The digestion was performed for 30 min at 37
• C with continuous vortex-mixing. The suspension was filtered through a 250 µm pore-size nylon filter (Sintab, Oxie, Sweden) into sterile 10 ml tubes. The filtered suspension was kept on ice for 30 min to let the mature adipocytes float up. The top layer of the suspension was removed, and the rest of the suspension was filtered through a 25 µm pore-size nylon filter (Sintab) and re-centrifuged at 700 g for 10 min, to pellet the precursor cells. The pellet was resuspended in 5 ml of DMEM and centrifuged at 700 g for 10 min. The pellet was then suspended in culture medium (0.5 ml/animal). The cells were cultured in six 10-cm 2 -well plates (Corning); 1.8 ml of culture medium was added to each well before 0.2 ml (cells corresponding to 0.4 animals) of cell suspension was added. The culture medium was DMEM with 10 % (v/v) newborn calf serum (Flow Laboratories, McLean, VA, U.S.A.), 4 nM insulin, 25 µg/ml sodium ascorbate, 10 mM Hepes, 4 mM glutamine, 50 units/ml penicillin and 50 µg/ml streptomycin. The cells were grown at 37
• C in an atmosphere of 8 % CO 2 in air with 80 % humidity. The medium was changed on day 1 and then every second day. The medium was pre-warmed to 37
• C before changing. The medium was not changed on the same day as the cells were harvested. The experiments were performed on different days of culture, as indicated in each individual experiment.
Analysis of mRNA levels
After the experiments, the medium was discarded and the cells were harvested from each well with 1 ml of Ultraspec (Biotecx Laboratories, Houston, TX, U.S.A.) as described in the manufacturer's protocol. The RNA obtained was examined by PCR or Northern blotting.
For quantitative real-time PCR, the first-strand cDNA was first synthesized as described previously [12] . RNA expression was then quantified by real-time quantitative PCR using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). Each PCR reaction contained, in a final volume of 25 µl, 1.5 µl of first-strand cDNA, 12.5 µl of 2× SYBR Green PCR Master Mix (Applied Biosystems) and 7.5 pmol of each primer [for PPARγ 1, forward, 5 -GGA CTG TGT GAC AGA CAA GAT TTG A-3 and reverse, 5 -CTG AAT ATC AGT GGT TCA CCG C-3 (GenBank ® accession number U01841); for PPARγ 2, forward, 5 -CTC TGT TTT ATG CTG TTA TGG GTG A-3 and reverse, 5 -GGT CAA CAG GAG AAT CTC CCA G-3 (GenBank ® accession number U09138); for TFIIB (transcription factor IIB), forward, 5 -GTT CTG CTC CAA CTT TTG CCT-3 and reverse, 5 -TGT GTA GCT GCC ATC TGC ACT T-3 (GenBank ® accession number NM_145546); primers from DNA Technology A/S, Aarhus, Denmark]. All reactions were performed using the following cycling conditions: 50
• C for 2 min and 95
• C for 10 min, followed by 40 cycles at 95
• C for 15 s and 60
• C for 1 min. PCR was carried out in 96-well plates and in triplicate.
The relative amounts of all mRNAs were calculated using the comparative CT method.
For Northern blotting, total RNA was separated on an agarose gel (1.25 %) containing 20 mM Mops (pH 7.0) and 6.7 % formaldehyde. Ethidium bromide (1 mg/ml) was added to the gel to examine the distribution of RNA in UV light. The gel was run for 2-3 h at 100 V. The RNA was transferred on to a Hybond-N membrane (Amersham Biosciences) by capillary blotting overnight. The membrane was prehybridized at 42
• C for at least 1 h in 10 ml of hybridization solution containing 5× SSC (pH 7.0) (1× SSC is 0.15 M NaCl/0.015 M sodium citrate), 5× Denhardt's (1× Denhardt's is 0.02 % Ficoll 400/0.02 % polyvinylpyrrolidone/0.02 % BSA), 0.5 % (w/v) SDS, 50 mM sodium phosphate (pH 6.5), 50 % formamide and 100 µg/ml degraded herring sperm DNA. Hybridization of the membranes was performed overnight at 42
• C in a fresh hybridization solution with the addition of denaturated probe, [ 32 P]dCTP-labelled cDNA, corresponding to mouse PPARγ mRNA, labelled by random priming (Amersham Biosciences). The PPARγ cDNA contained 454 bp corresponding to positions 127-581 in the published PPARγ 2 sequence with GenBank ® accession number U09138 (a gift from Dr Bruce Spiegelman, Dana Faber Cancer Research Institute, Boston, MA, U.S.A.). The identity of the probe was confirmed by sequencing. The probe matched the mouse mRNA regions that correspond to exon 1 and exon 2, which are exons common for PPARγ 1 and γ 2. The probe was thus not specific for PPARγ 2, but based on the results in Figure 1 (C), the outcome was referred to as PPARγ 2. After hybridization, the solution was removed and the membranes were washed twice for 30 min at room temperature in a solution of 2× SSC and 0.2 % (w/v) SDS, followed by washing twice for 60 min at 45
• C in 0.1× SSC and 0.2 % (w/v) SDS. The membranes were sealed in a plastic envelope and then exposed to a PhosphoImager screen and scanned in a Molecular Dynamic's PhosphoImager 425 S. Specific mRNA signals were analysed with the ImageQuant software. For analysis, the curve-fitting option of the KaleidaGraph 3.0 application was used as indicated in the legends to the Figures . The uncertainties given are those of the KaleidaGraph estimates.
Analysis of PPAR protein levels
Brown adipocytes were treated with 1 µM noradrenaline for the specified times. After the treatment, the cell cultures were washed twice in PBS and then harvested in a lysis buffer containing 62.5 mM Tris/HCl (pH 6.8), 2 % (w/v) SDS, 10 % (v/v) glycerol and a protease inhibitor cocktail (Complete Mini; Roche). After sonication, the concentration of the soluble proteins was determined (using the method of Lowry) in the sample, and 1/10 vol of lysis buffer supplemented with 0.5 M dithiothreitol and 1 % (w/v) Bromophenol Blue was added to each sample. Proteins (30 µg) were separated in 12 % polyacrylamide gels containing SDS, and transferred on to a PVDF membrane (Amersham Biosciences) in 48 mM Tris/HCl, 39 mM glycine, 0.037 % (w/v) SDS and 15 % (v/v) methanol using a semi-dry electrophoretic transfer cell (Bio-Rad). Following transfer, the membrane was stained with Ponceau S for examination of equal loading of proteins. After washing, the membrane was blocked in 5 % (w/v) dried milk overnight at 4
• C. The membrane was then incubated in 1:500 diluted primary antibody. The antibody against PPARγ (sc-7273) was obtained from Santa Cruz Laboratories, while the antibody against PPARα (MA1-822) was from Affinity BioReagents. The immunoblots were visualized with horseradish-peroxidase-conjugated secondary antibodies (Cell Signaling Technology) and ECL ® (enhanced chemiluminescence; Amersham Biosciences) in The value at day 5 was in each experiment set to 100 %, and the PPARγ mRNA levels on the other days were expressed relative to this value in each individual experiment. Values with broken lines are from an additional experiment in which PPARγ mRNA levels (᭺) and noradrenaline-induced UCP1 mRNA levels () were determined in parallel (means from duplicate samples, normalized to 18 S RNA); these data were also adjusted to 100 % for the day of highest mRNA level. (C) PPARγ 1 and PPARγ 2 mRNA levels in brown adipocytes. Cultures were grown as in (A) and then treated with 1 µM noradrenaline or not for 2 h. RNA was extracted and PPARγ 1, PPARγ 2 and TFIIB mRNA levels were determined by real-time PCR as described in the Experimental section. The PPARγ 1 and PPARγ 2 mRNA levels were normalized to the TFIIB mRNA levels in each sample. The mean total amount of PPARγ mRNA in untreated cells was set to 100 %. Results are means + − S.E.M. of triplicate samples; * indicates that the effect of noradrenaline on PPARγ 2 was significant (P 0.05), whereas there was no significant effect on PPARγ 1 levels. (D) Relative effect of noradrenaline on the PPARγ 2 mRNA level during cell differentiation. Values were calculated from the data in (A), adjusting the non-treated PPARγ 2 mRNA to 100 % for each day and indicating the relative effect of noradrenaline for each day.
a CCD (charge-coupled device) camera. The blots were quantified using the Image Gauge V3.45 program (Fuji Film).
Chemicals
Noradrenaline bitartrate (Arterenol), A23187, PMA, pertussis toxin, cycloheximide, actinomycin D, forskolin, isoprenaline, 8-bromo-cAMP, CGP-12177, cirazoline, CL-316243 and Ly-294002 were obtained from Sigma/RBI; H89, PP2, PD-98059 and SB-202190 from Calbiochem. PMA, Ly-294002, H89, PP2, PD-98059, SB-202190 and forskolin were dissolved in DMSO.
RESULTS

PPARγ mRNA levels in spontaneously differentiating brown adipocytes
To examine whether noradrenaline differentially influences PPARγ gene expression in brown pre-adipocytes compared with differentiated brown adipocytes, brown pre-adipocytes were grown and developed in culture. Under the conditions used, the fibroblast-like pre-adipocytes proliferate until they are confluent at day 5-6 and then differentiate to mature brown adipocytes in a spontaneous, but highly temporally and qualitatively reproducible, way [10, 11, 13] .
Significant levels of PPARγ mRNA were observed already in the morphologically undifferentiated cells at day 3 ( Figure 1A ). In a compilation of a series of experiments ( Figure 1B) , it is seen that the level of PPARγ mRNA increased somewhat during the cell culture, to reach a maximum on day 5 of culture. The expression of the established brown adipocyte differentiation marker, noradrenaline-induced UCP1 mRNA, is also displayed in Figure 1(B) , together with the corresponding PPARγ levels; clearly, the maximal PPARγ expression coincides with the maturation phase of the cells. The presence of PPARγ already in brown preadipocytes and the small increase slightly before the accelerated expression of differentiation markers is in accordance with earlier observations [13] . PPARγ expression is thus maximal at the time of the switch from the brown pre-adipocyte to the mature brown adipocyte stage.
To examine which PPARγ transcripts were expressed in these cells, RNA samples from the cell cultures with maximal PPARγ expression level were analysed by quantitative real-time PCR ( Figure 1C , grey bars). As seen, practically no PPARγ 1 mRNA was found in the cell cultures; 95 % of the PPARγ transcript present was PPARγ 2 mRNA. For comparison, we also examined the PPARγ 1/PPARγ 2 mRNA ratio in some mouse tissues. Similarly to the case in the brown adipocytes in culture, PPARγ 2 was the dominant isoform both in mouse brown adipose tissue (> 70 %) and white adipose tissue (> 75 %), whereas in liver, the PPARγ 1 isoform was dominant (> 90 %) (results not shown). Based on the results in Figure 1 (C), we refer in the following to the detected species on Northern blots as PPARγ 2.
Effect of noradrenaline on PPARγ 2 mRNA levels
As shown in Figures 1(A) and (D), PPARγ mRNA levels were decreased markedly upon noradrenaline treatment. Real-time PCR established that the reduction observed was due to a decrease in the levels of PPARγ 2, and was not counteracted by an increase in PPARγ 1 ( Figure 1C ). The noradrenaline-induced downregulation of PPARγ 2 mRNA levels was observed in proliferative as well as in differentiating cells ( Figures 1A and 1D) ; there was thus no switch in the qualitative response between pre-adipocytes and mature adipocytes concerning adrenergic regulation of PPARγ 2 mRNA levels. The absence of a switch is in contrast with the qualitative switch from noradrenaline promoting cell proliferation in brown pre-adipocytes to noradrenaline promoting cell differentiation in mature brown adipocytes, to the switch from β 1 -adrenoceptors being coupled to adenylate cyclase to β 3 -adrenoceptors being the coupled ones [14] , and to the switch from noradrenaline decreasing C/EBPα (CCAAT/enhancer-binding protein α) gene expression to noradrenaline increasing it [15] .
For further investigations of the effect of noradrenaline, cells at day 5 in culture were used. To examine the time course of the noradrenaline effect, the cell cultures were treated with noradrenaline, and the levels of PPARγ 2 mRNA were determined after various lengths of time. The combined results from a series of such experiments are presented in Figure 2 (A). There was a marked lagtime of nearly 1 h before a noradrenaline effect was observable, an indication that a complex mediatory system was involved. The lagtime was followed by a marked successive decrease in mRNA, lasting for about 1 h. The PPARγ 2 mRNA levels then remained low for about 2 h, and then successively increased. The mRNA levels regained control values after about 24 h; with a higher dose of noradrenaline, a doubling of mRNA levels has been reported after 24 h of treatment [16] .
To obtain a dose-response curve for the noradrenalineinduced decrease in PPARγ 2 mRNA levels, cultures were treated for 3 h with different concentrations of noradrenaline ( Figure 2B ). The effect of noradrenaline was clearly dose-dependent, monophasic and saturable. The PPARγ 2 mRNA levels were reduced maximally to approx. 50 %, even with high concentrations of noradrenaline. The calculated EC 50 value for noradrenaline was 80 + − 11 nM. This is similar to that of the noradrenaline-induced increase in the gene expression of VEGF (vascular endothelial growth factor) A [17] and ribonucleotide reductase subunit R2 [18] , but higher than the EC 50 (approx. 10 nM) for stimulation of gene expression of UCP1 [11] and the β 1 -adrenergic receptor [19] , and much higher than the EC 50 for the noradrenaline-induced decrease in β 3 -adrenoceptor mRNA (approx. 1 nM) [19, 20] .
The effects of noradrenaline-induced repression of PPARγ 2 gene expression on PPARγ protein levels
To study whether the norepinephrine-induced repression of PPARγ 2 gene expression resulted in lower levels of the corresponding protein, we examined samples of norepinephrine-treated brown adipocytes by immunoblotting. The curve is based on two to nine independent experiments (except at 21 h, where only one was performed) in duplicate wells. In each experiment, the PPARγ 2 mRNA value from non-treated cells was set to 100 % and the other values were expressed relative to this. Results are means + − S.E.M. The curve was drawn by the 'smooth' function of KaleidaGraph. (B) Dose-response curve. Brown adipocyte cultures (day 5) were treated with the indicated concentrations of noradrenaline for 3 h and analysed as in Figure 1(A) . Results are means + − S.E.M. for five independent experiments. In each experiment, the control level was set to 100 % and the other values were expressed relative to this. The results were analysed for adherence to Michaelis-Menten kinetics with the formula: mRNA NA = 100 % − mRNA max · [noradrenaline]/(EC 50 + [noradrenaline]) (excluding the 100 µM value). The EC 50 value thus obtained was 80 + − 11 nM noradrenaline and the maximal decrease ( mRNA max ) was 55 + − 1 %.
Using a commercial antibody against PPARγ (sc-7273), which can recognize both PPARγ 2 and PPARγ 1, we observed that the brown adipocyte protein extracts displayed three bands (Figure 3A) . The upper two bands were identified as the phosphorylated and non-phosphorylated forms of PPARγ 2. This was based on the lower of these two having the expected molecular mass of PPARγ 2 (56 kDa) [21] , and in a parallel immunoblot, protein extracts from 3T3-L1 adipocytes and from cells overexpressing PPARγ 2 protein displayed similar bands (results not shown). As a negative control ( Figure 3A) , we used a protein extract from mouse heart, as heart does not express PPARγ 2 [22] . Treatment of brown adipocyte protein extracts with calf intestinal phosphatase before electrophoresis resulted in the disappearance of the upper of these bands (results not shown), confirming the phosphoprotein nature of this band. The intensities of both these bands were decreased markedly after noradrenaline stimulation ( Figure 3A, and see below) . The anti-PPARγ antibody also recognized a band of a molecular mass of 52 kDa. The intensity of this band was also decreased markedly after noradrenaline treatment ( Figure 3A) . The molecular mass of both PPARγ 1 and PPARα is approx. 52 kDa, and due to the similarity between PPARγ and PPARα, the possibility existed that the anti-PPARγ antibody also recognized PPARα. PPARα is also expressed in brown adipocytes [13] , but as demonstrated above ( Figure 1C ), PPARγ 1 mRNA is nearly absent from the brown adipocytes examined in the present study, and PPARγ 1 protein would therefore not a priori be expected. Attempts to separate PPARα and PPARγ 1 were made with larger gels and utilizing protein from cell lines retrovirally transduced with PPARα and PPARγ , but a separation was not achieved (results not shown).
Therefore, to examine the possibility that the 52 kDa band resulted from non-specific interaction of the anti-PPARγ antibody with PPARα, we analysed samples using a commercial antibody (MA1-822) against PPARα. As seen ( Figure 3B ), this antibody recognized a band at ≈ 52 kDa in heart preparations, in accordance with the reported high expression of PPARα in this tissue [22] . Similarly, this anti-PPARα antibody recognized a protein in the brown adipocyte extracts, principally in agreement with brown adipocytes expressing the mRNA of PPARα [13] . Notably, the band recognized by the anti-PPARα antibody did not diminish in intensity as an effect of noradrenaline treatment ( Figure 3B) .
However, since the anti-PPARγ antibody could not recognize any protein of 52 kDa in the heart preparation ( Figure 3A ) that clearly contained very significant amounts of PPARα ( Figure 3B) , we conclude that the band recognized by the anti-PPARγ antibody at 52 kDa cannot be PPARα; it is therefore probably PPARγ 1. This conclusion is unexpected, considering the > 20-fold predominance of PPARγ 2 mRNA levels over PPARγ 1 mRNA levels in this system ( Figure 1C ). It is, of course, possible that the translation efficiency is 20-fold higher for PPARγ 1 than for PPARγ 2 mRNA. However, alternatively, since the mRNA template for PPARγ 2 also contains the full template for PPARγ 1, including an undisturbed translation-initiation sequence, we suggest that the PPARγ 1 is formed from the PPARγ 2 template. The levels of PPARγ 1 and PPARγ 2 are about the same, as judged from the intensities on the immunoblot ( Figure 3A ). This may be interpreted that the translation machinery, with equal probability, commences at the PPARγ 2 and PPARγ 1 initiation sites on the PPARγ 2 mRNA; alternatively, each protein could be translated in parallel from both the PPARγ 2 and the PPARγ 1 initiation sites, as has been discussed for other proteins [23] .
In Figure 4 (A), an example of a time curve of the effect of noradrenaline on PPARγ protein levels is shown, and in Figure 4 (B), a compilation of results from several experiments with different, overlapping, time points is displayed. It is seen that both PPARγ 2 and PPARγ 1 protein amounts decrease, finally reaching a level of approx. 50 % of the starting value; this level is not statistically significantly different for PPARγ 2 and PPARγ 1 (in the analysis, the phosphoPPARγ 2 and non-phosphorylated PPARγ 2 bands were combined). A 50 % reduction is what would be expected from the 50 % reduction in PPARγ 2 mRNA observed after noradrenaline treatment ( Figures 1C, 2A and 2B ). The curve shapes adhere to being delayed reflections of the kinetics of the changes in PPARγ 2 mRNA levels ( Figure 2A) . Remarkably, the decrease in PPARγ 1 protein level was somewhat more rapid than the decrease in PPARγ 2 level (the half-lives of PPARγ 2 protein and PPARγ 1 protein do not have to be identical even if they are both translated from the same template). Taken together, these kinetic data support the suggestion that PPARγ 2 and PPARγ 1 are both translated from PPARγ 2 mRNA.
We therefore conclude that the noradrenaline-induced repression of PPARγ gene expression that leads to a reduction in PPARγ 2 mRNA levels, and also results in a parallel, but delayed, decrease in the protein levels of PPARγ 2 and PPARγ 1. The mechanism behind the repression of PPARγ gene expression was therefore studied further.
The half-life of PPARγ 2 mRNA
The decrease in PPARγ 2 mRNA levels induced by noradrenaline could be due either to an increase in the degradation rate of PPARγ 2 mRNA or to an inhibition of the transcription of the PPARγ 2 gene. To discriminate between these possibilities, the effects of noradrenaline were compared with those of the RNA synthesis inhibitor actinomycin D. The inhibitor was added to the cultures at a concentration that fully blocks noradrenaline-induced expression of the UCP1 gene [24] . The results of these experiments are shown in Supplementary Figure 1 (see http://www. BiochemJ.org/bj/382/bj3820597add.htm). The effect of noradrenaline addition in itself was in accordance with the time curve in Figure 2 (A), with a lagtime of approx. 1 h and with a successive decrease thereafter, analysed here to correspond to a half-life of 42 min (range 38-47 min). The effect of actinomycin D was similar: the PPARγ 2 mRNA levels decreased with a half-life of 35 min (range 27-50 min). When the cells were exposed to actinomycin D in combination with noradrenaline, the mRNA halflife was 43 min (range 39-46 min). As there was no significant difference between the half-lives under these three conditions, these experiments indicate that cessation of transcription is an adequate explanation for the decrease in PPARγ 2 mRNA levels after noradrenaline stimulation.
Identification of the adrenergic receptors mediating the noradrenaline effect
To identify the adrenergic receptors involved in the mediation of the noradrenaline-induced down-regulation of PPARγ 2 mRNA levels, cell cultures were treated with various adrenergic agents.
To examine if the α 1 -adrenergic receptor could be involved, the cultures were treated with the α 1 -adrenergic receptor agonist cirazoline. However, cirazoline was not able to mimic the noradrenaline-induced decrease in PPARγ 2 mRNA levels (Figure 5A) . Effects of the second messengers known to mediate the α 1 -adrenergic effects in these cells, i.e. calcium [25, 26] and protein kinase C [27] , were also investigated. The intracellular levels of calcium in the brown adipocytes were elevated by the calcium ionophore A23187 [28] , but this did not lead to repression of PPARγ 2 gene expression ( Figure 5A ). Similarly, protein kinase C was activated by the phorbol ester PMA [27] , but this did not influence PPARγ 2 gene expression ( Figure 5A ). Thus the noradrenaline effect on PPARγ 2 mRNA levels is not mediated via the α 1 -adrenoceptor or α 1 -associated pathways.
To examine whether stimulation of the β-adrenergic receptors was involved, the effect of the general β-agonist isoprenaline was investigated ( Figure 5B ). Isoprenaline could mimic the effect of noradrenaline, indicating that this effect of noradrenaline was Primary cultures of brown adipocytes were grown in culture. On day 5, the indicated agonists were added to the cell cultures 3 h before harvesting. Total RNA was isolated and the PPARγ 2 mRNA levels were analysed as in Figure 1(A) . (A) α 1 -Adrenergic pathways were analysed by treatment with noradrenaline (0.1 µM; n = 7), the α 1 -adrenergic receptor agonist cirazoline (cir; 1 µM; n = 7), the calcium ionophore A23187 (A23; 1 µM; n = 2), and the protein kinase C agonist PMA (50 nM; n = 2). The mean PPARγ 2 mRNA level in untreated cells (C) was set to 100 % in each series. (B) β-Adrenergic pathways were analysed by treatment with noradrenaline (1 µM; n = 7), with the β-adrenergic receptor agonist isoprenaline (iso; 1 µM; n = 3), the β 3 -adrenergic receptor agonists CGP-12177 (CGP; 10 µM; n = 4) and CL-316243 (CL; 1 µM; n = 3), with forskolin (forsk; 5 µM; n = 4) or 8-bromo-cAMP (8-Br; 0.1 µM; n = 1). In (A) and (B), ***, ** and * indicate P < 0.001, P < 0.01 and P < 0.05 respectively for effect of treatment (Student's paired t test). Results are means + − S.E.M.
mediated via β-receptors. In these brown adipocytes on day 5, both β 1 -and β 3 -adrenergic receptors are present, but no β 2 -adrenergic receptors [14, 19] . To test whether the β 3 -adrenergic receptors could mediate the signal, the β 3 -adrenoceptor agonists CGP-12177 and CL-316243 were used. These β 3 -adrenergic receptor agonists gave similar results to those of isoprenaline or noradrenaline ( Figure 5B ). Thus the β 3 -adrenoceptors were competent in mediating the adrenergic signal. However, the β 3 -adrenergic receptors as such (as compared with the β 1 -adrenergic receptors) were not essential for the adrenergic effect, because noradrenaline was able to decrease PPARγ 2 mRNA levels already in cells that had only been 3 days in culture (Figure 1 ), i.e. before the β 3 -adrenoceptors are expressed and when only β 1 -adrenoceptors are found [14] . Classically, β-adrenergic receptors are considered to be coupled to G s -proteins that stimulate adenylate cyclase, leading to an increase in the level of the second messenger cAMP. To investigate whether stimulation of this pathway could mimic the effects of noradrenaline stimulation, the brown adipocytes were exposed to the adenylate cyclase activator forskolin or to the cAMP analogue 8-bromo-cAMP. Both agents induced a down-regulation of the PPARγ 2 mRNA levels to about the same degree as did noradrenaline treatment ( Figure 5B ). Thus the β-adrenergic effect is fully mimicked by cAMP and does not require receptor activation. As the cAMP level obtained after forskolin is markedly higher than that after noradrenaline [26] , the extent of repression of PPARγ 2 gene expression (to approx. 50 % of control) was apparently not limited by the amount of cAMP, but by a process downstream from cAMP.
Investigation of possible β-adrenergic-receptor-associated signalling pathways
The intracellular pathways involved in the noradrenalineinduced down-regulation in PPARγ 2 mRNA levels were investigated further by studying the effects of pathway-specific intracellular inhibitors. For this, the cells were pre-treated with these inhibitors 1 h before and during a 3 h exposure to noradrenaline (see Supplementary Figure 2 at http://www.BiochemJ.org/bj/382/ bj3820597add.htm). Again, exposure to noradrenaline in otherwise untreated cultures led to a reduction in PPARγ 2 mRNA levels to about 50 % (Supplementary Figure 2A) . In Supplementary Figure 2(B) , the effect of noradrenaline, i.e. the PPARγ 2 mRNA value, is depicted, for easier comparison of this parameter between the different inhibitors.
In 3T3-F442A adipocytes, β 3 -adrenoceptors have been suggested to be able to directly stimulate G i -proteins [29, 30] . If a β 3 -adrenergic-receptor-coupled G i -protein pathway was involved in the mediation of the noradrenaline-induced repression of PPARγ 2 gene expression in the brown adipocytes studied here, inhibition of G i -proteins by pertussis toxin should inhibit the noradrenaline effect; this was clearly not the case (Supplementary Figure 2) . This postulated β 3 -adrenoceptor-coupled G i -protein pathway has also been proposed to directly stimulate PI3K (phosphoinositide 3-kinase) in adipocytes [29] , and this kinase, stimulated either in this way or through the classical β-adrenergic receptor/G s /cAMP pathway, could then mediate the repression. However, when the cultured brown adipocytes were treated with the PI3K inhibitor Ly-294002 at a concentration that inhibits insulin-induced glucose uptake in cultured brown adipocytes [31] , the noradrenaline effect on PPARγ 2 mRNA levels was unchanged (Supplementary Figure 2) .
In cultured brown adipocytes, PKA (protein kinase A) further mediates the cAMP signal towards UCP1 gene expression [32] . To investigate whether PKA also mediates the noradrenaline effect on PPARγ 2 gene expression, the PKA inhibitor H89 was used at a concentration that abolishes noradrenaline-induced UCP1 gene expression [32] . H89 abolished the noradrenaline-induced decrease in PPARγ 2 mRNA levels (Supplementary Figure 2B) . This outcome is thus compatible with the noradrenaline-induced decrease in PPARγ 2 mRNA levels being PKA-mediated, but nonspecific effects of inhibitors can never be totally excluded. β 3 -adrenoceptor pathways (as well as α 1 -adrenoceptor pathways) activate the cytosolic tyrosine kinase Src in brown adipocytes [33] . Therefore the Src inhibitor PP2 was used at a concentration that fully abolishes noradrenaline-induced and Src-mediated phosphorylation of ERK1/2 (extracellular-signalregulated kinase 1 and 2) in cultured brown adipocytes [17] . However, PP2 had only a marginal effect on the noradrenalineinduced decrease in PPARγ 2 mRNA levels.
In brown adipocytes, noradrenaline activates the MAPK (mitogen-associated protein kinase) ERK1/2 through MEK (MAPK/ ERK kinase) activation [34] . That activation of ERK1/2 may be mediatory for the effect of noradrenaline on PPARγ 2 levels may be suggested, since PPARγ 2 is phosphorylated by MAPK in adipocyte cell lines, and the phosphorylated PPARγ 2 suppresses the transcriptional activity of PPARγ 2 and thus adipogenesis [35] . However, the MEK inhibitor PD-98059, at a concentration that inhibits the noradrenaline effect on ERK1/2 phosphorylation [34] , had no effect on the noradrenaline-induced decrease on PPARγ 2 mRNA levels (Supplementary Figure 2) .
In brown adipocytes, noradrenaline also activates p38 MAPK [36] . Therefore the p38 inhibitor SB-202190 was added to the cells (Supplementary Figure 2B) , but this did not have a significant effect on the noradrenaline-induced repression of PPARγ 2 gene expression (Supplementary Figure 2) .
Thus the data observed were compatible with a β-adrenergic pathway, including cAMP and PKA activation, but not involving G i , PI3K, Src, ERK1/2 or p38 MAPK.
Further mediation of the adrenergic signal requires protein synthesis
As a lagtime was observed for the noradrenaline-induced repression of PPARγ 2 gene expression (Figure 2A) , it is feasible that the effect requires the synthesis of a new protein, rather than being due to a direct effect on existing proteins. The cultures were therefore treated with the protein synthesis inhibitor cycloheximide at a concentration which blocks translation in differentiated brown adipocytes in culture [37] . Cycloheximide fully blocked the ability of noradrenaline to decrease PPARγ 2 mRNA levels (Supplementary Figure 3 at http://www.BiochemJ.org/bj/ 382/bj3820597add.htm). Additionally, after a lagtime of about 1 h, it evoked in itself (or equally in the presence of noradrenaline) an increase in PPARγ 2 mRNA levels. The levels were doubled after a further 1 h and may apparently increase further during the next 6-12 h [13] . These results indicate that protein synthesis is required for mediation of the adrenergic signal and could also imply that a continually synthesized protein with a rapid turnover leads to tonic repression of PPARγ 2 mRNA synthesis.
DISCUSSION
In the present study, we found that the PPARγ mRNA isoform expressed in brown adipocytes was predominantly PPARγ 2. In primary cultures of brown adipocytes, PPARγ 2 mRNA was found already in the undifferentiated brown pre-adipocytes. The expression peaked at day 5, just as the cells reached confluence and entered differentiation. Noradrenaline induced a transient decrease in PPARγ 2 mRNA levels in both brown pre-adipocytes and in brown adipocytes, and this resulted in parallel decreases in the protein levels of phosphoPPARγ 2, PPARγ 2 and PPARγ 1. A tentative pathway for the intracellular mediation of the noradrenaline-induced repression of gene expression may be formulated (see Supplementary Figure 4 at http://www.BiochemJ.org/ bj/382/bj3820597add.htm).
PPARγ 2 mRNA dominance in brown adipocytes
We found that the PPARγ 2 mRNA levels exceeded the PPARγ 1 mRNA levels approx. 20-fold in the cultured brown adipocytes. The relative levels of PPARγ 1 mRNA compared with those of PPARγ 2 mRNA have not previously been determined in brown adipocytes, but a predominant expression of PPARγ 2 (compared with that of PPARγ 1) in mouse adipocyte cell lines has been mentioned previously [2] . In mouse brown and white adipose tissue, we also observed a clear predominance of PPARγ 2 mRNA (as mentioned in the Results section), and, similarly, in human white adipose tissue, a 20-fold excess of PPARγ 2 mRNA has been found [38] . However, there are also reports that roughly equal levels of PPARγ 1 and PPARγ 2 mRNA, or a predominance of PPARγ 1, are found in mouse [39] and human [40] white adipose tissue. These qualitative differences in the PPARγ 1/PPARγ 2 mRNA ratios reported (if not methodological) may be related to the prevailing hormonal status.
The noradrenaline effect
When brown pre-adipocytes or adipocytes were treated with noradrenaline, down-regulation of the PPARγ 2 mRNA levels occurred within the first 2-4 h after treatment (Figures 1 and 2) .
The down-regulation was transient. In the brown adipocyte-like cell line HIB-1B, both a noradrenaline-induced decrease [6] and a noradrenaline-induced increase [13] in PPARγ 2 mRNA levels have been noted (4-5 h after stimulation), perhaps reflecting variability in the characteristics of the cell line and phenotypic drift in the cell line. The noradrenaline-induced repression observed here in brown adipocyte primary cultures may be related to reported effects of exposure to cold on PPARγ 2 gene expression in brown adipose tissue. Cold exposure leads to increased release of noradrenaline in situ in brown adipose tissue, and cold exposure has been reported to induce a decrease in PPARγ 2 mRNA levels [41, 42] .
Noradrenaline stimulates proliferation in brown pre-adipocytes and differentiation in mature brown adipocytes. Therefore, in accordance with present formulations concerning a positive role of PPARγ 2 for cell differentiation and a concurrent inhibitory role in cell proliferation, a shift from a noradrenaline-induced repression of transcription in brown pre-adipocytes to a noradrenaline-induced augmentation of transcription in differentiated brown adipocytes would have been expected. A notable observation here was therefore the lack of a switch in the qualitative response to noradrenaline between brown pre-adipocytes and brown adipocytes ( Figure 1 ).
Cellular mediation of the noradrenaline effect
Based on the observations reported here, we suggest a pathway for the intracellular signalling from adrenergic stimulation to repression of PPARγ 2 gene expression and decreased levels of PPARγ 2 and PPARγ 1, as depicted in Supplementary Figure 4 . The basis for this pathway is as follows.
Although α 1 -, α 2 -, β 1 -and β 3 -adrenoceptors are present in brown adipocytes, the experiments with adrenergic agonists and inhibitors or activators of the corresponding signalling processes ( Figure 5 and Supplementary Figure 2 ) demonstrated that only β-adrenoceptors (both β 1 -and β 3 -adrenoceptors) could mediate the repression. cAMP levels are increased after noradrenaline stimulation in these cell cultures [26, 43] . The repression of PPARγ 2 mRNA levels is probably mediated via this cAMP, as a repression could also be induced by forskolin or 8-bromocAMP ( Figure 5B ). In contrast, in HIB-1B pre-adipocytes [6] and in rabbit type II pneumonocytes [44] , dibutyryl-cAMP increased PPARγ 2/γ 1 mRNA levels. Thus no general response of the PPARγ 2 gene to cAMP increases can be formulated.
PKA is activated by noradrenaline/cAMP in brown adipocytes [32] . Based on investigation of the effects of different kinase inhibitors (Supplementary Figure 2) , it seems likely that the noradrenaline-induced decrease in PPARγ 2 mRNA levels is mediated by PKA, since the effect was totally abolished by the inhibitor H89, but not by any other inhibitor tested.
The response could proceed further via CREB (cAMPresponse-element-binding protein) phosphorylation. Noradrenaline, through PKA activation, induces phosphorylation of the transcription factor CREB also in primary cultures of brown adipocytes [45, 46] . However, in other cell types (3T3-L1 cells), it has been observed that a constitutively active CREB construct induces (not represses) the expression of PPARγ 2 [47] , and dominant-negative CREB constructs inhibit PPARγ 2 gene expression [47] . As noradrenaline inhibits PPARγ 2 transcription in the brown adipocytes used in the present study, it is unlikely that CREB is a direct activator of PPARγ 2 gene expression.
In this context, it may be noted that the noradrenaline effect has a lagtime (Figure 2A ), suggesting that an activation/inactivation of an existing transcription factor cannot easily explain the mediation; instead there could be a requirement for protein synthesis in the mediation process. Inhibition of protein synthesis indeed abolished the effect of noradrenaline (Supplementary Figure 3) . As inhibition of protein synthesis not only abolished the noradrenaline effect, but also led to superinduction of PPARγ 2 (Supplementary Figure 3) [13], the results can be interpreted as indicating the existence of a mediatory protein. Although there could be other effects of protein synthesis inhibition [48] , the data would be compatible with a mediatory protein being expressed at a basal level, having a relatively short half-life (< 1 h) and acting as a transcriptional repressor on the PPARγ 2 gene. When protein synthesis is inhibited, the regulatory protein would successively disappear, and so thus would repression, leading to increased levels of PPARγ 2 mRNA. On the other hand, noradrenaline stimulation (e.g. through CREB phosphorylation) could enhance the rate of synthesis of the mediatory repressor protein, leading to an increased repression of PPARγ 2 transcription.
Both PPARγ 2 and PPARγ 1 protein levels are repressed by noradrenaline
Although noradrenaline stimulation led to a marked reduction in PPARγ 2 mRNA levels, this reduction could be without significant effects on cellular functions, if it were not reflected in an altered level of PPARγ 2 protein. As the repression is transient (Figure 2A) , the protein levels could remain nearly unchanged if the half-life of PPARγ 2 was long. However, direct investigation of PPARγ 2 protein levels clearly demonstrated that the decreased mRNA level was fully reflected in a decreased PPARγ 2 level (Figures 3 and 4) . Thus regulatory effects of the altered expression may be envisaged.
Although only PPARγ 2 mRNA is found in significant amounts in the brown adipocytes used in the present study, the immunoblots revealed that PPARγ 1 protein was present in equal amounts to PPARγ 2 protein (Figures 3 and 4) . The most likely explanation for this phenomenon is that the PPARγ 2 mRNA is translated with equal probability from the PPARγ 2 initiation site and from the PPARγ 1 initiation site (that is found unperturbed in the PPARγ 2 mRNA). Whether this is a specific phenomenon for the brown adipocytes used in the present study is unknown, but the potential for the dual outcome of translation of the PPARγ 2 mRNA has been evident since the first characterization of the PPARγ 2 splice variant [2] .
The physiological function of noradrenaline-induced repression of PPARγ 2 gene expression
The physiological role of the noradrenaline-induced repression of PPARγ 2 gene expression reported in the present paper, and the ensuing decreases in PPARγ 2 and PPARγ 1 protein, is only partially understandable. A repression of PPARγ 2 gene expression in brown pre-adipocytes is functionally explainable based on the proliferative effect of noradrenaline [43] and the antiproliferative role ascribed to PPARγ . However, the persistence of the effect in mature brown adipocytes, in which cell proliferation is not induced by noradrenaline [43] , makes this explanation for the noradrenaline-induced repression less probable.
If the differentiation-promoting effect of PPARγ is accepted, the suppressed expression of PPARγ 2 by noradrenaline should have a de-differentiating effect on brown adipocyte characteristics. However, a general differentiation-promoting effect of noradrenaline is seen in the brown adipocytes. For instance, even though there is a PPRE site, e.g. in the UCP1 promoter [6, 7] , UCP1 gene expression is markedly induced, and not even transiently repressed during noradrenaline stimulation [11] ; the explanation concerning UCP1 may be that this PPRE site could be stimulated primarily by PPARα [7] ; PPARα is not decreased by noradrenaline treatment ( Figure 3A) . Although brown adipocytes share traits with white adipocytes and adipocyte-like cell lines, the final differentiation process of brown adipocytes must necessarily be distinct from that of white adipocytes. Thus, whereas PPARγ is necessary for adipose conversion, the possibility exists that temporal repression of PPARγ 2 expression is a part of the events that promote acquisition of brown adipose traits (as compared with general adipose traits) during chronic noradrenaline stimulation of maturating brown adipocytes.
